Genotyping for Human Papillomavirus Types 16 and 18 in Women With Minor Cervical Lesions: A Systematic Review and Meta-analysis
The DOI matches its Crossref record, with a small difference in title or year; 57 of the 57 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High-risk human papillomavirus (hrHPV) testing to triage women with minor cervical lesions generates many referrals. PURPOSE: To evaluate the accuracy of genotyping for HPV types 16 and 18 and its utility as a second triage step after hrHPV testing in women with minor cervical lesions. DATA SOURCES: Searches of 4 bibliographic databases, without language restrictions, from 1 January 1999 to 1 February 2016. STUDY SELECTION: Studies involving women with atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesions (LSIL) who were triaged with tests for hrHPV and HPV 16/18 to find cervical intraepithelial neoplasia (grade ≥2 [CIN2+] or grade ≥3 [CIN3+]). DATA EXTRACTION: Independent study selection, extraction of data, and quality assessment by 2 reviewers. DATA SYNTHESIS: Twenty-four moderate- to good-quality studies involving 8587 women with ASC-US and 5284 with LSIL were found. The pooled sensitivity of HPV 16/18 genotyping for CIN3+ was about 70% for women with either ASC-US or LSIL. The pooled specificity (with a threshold of grade <2 CIN) was 83% (95% CI, 80% to 86%) for women with ASC-US and 76% (CI, 74% to 79%) for those with LSIL. The average risk for CIN3+ was 17% and 19% in HPV 16/18-positive women with ASC-US and LSIL, respectively, and was 5% in hrHPV-positive but HPV 16/18-negative women with either ASC-US or LSIL. LIMITATION: Methodological and technical heterogeneity among studies; insufficient data to assess accuracy of separate assays. CONCLUSION: Testing for HPV 16/18 to triage women with minor abnormal cytology is poorly sensitive but may be useful as a second triage test after hrHPV testing, with direct referral if the woman is positive for HPV 16/18. Whether colposcopy or repeated testing is recommended for hrHPV-positive but HPV 16/18-negative women depends on local decision thresholds that can be derived from pretest-posttest probability plots. PRIMARY FUNDING SOURCE: 7th Framework Programme of the European Commission.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interest has increased in the use of biomarkers, such as DNA methylation, to i mprove early detection of endometrial cancer. 31,32,170,171”
From Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women (2018) · cites this paper as [170]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Whiting, P., Rutjes, A. W., Reitsma, J. B., Bossuyt, P. M., & Kleijnen, J. (2003) · BMC Medical Research Methodology · doi:10.1186/1471-2288-3-25 · Cited by 3,592
The 2001 Bethesda System<SUBTITLE>Terminology for Reporting Results of Cervical Cytology</SUBTITLE>
Solomon, D. (2002) · JAMA · doi:10.1001/jama.287.16.2114 · Cited by 3,104
Deeks, J. J., Macaskill, P., & Irwig, L. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.01.016 · Cited by 2,910
Grading quality of evidence and strength of recommendations for diagnostic tests and strategies
Schünemann, H. J., Oxman, A. D., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G. E., Williams, J. W., Kunz, R., Craig, J., Montori, V. M., et al. (2008) · BMJ · doi:10.1136/bmj.39500.677199.ae · Cited by 1,782
Saslow, D., Solomon, D., Lawson, H. W., Killackey, M., Kulasingam, S. L., Cain, J., Garcia, F. A. R., Moriarty, A. T., Waxman, A. G., Wilbur, D. C., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21139 · Cited by 1,390
Self-citationSaslow, D., Solomon, D., Lawson, H. W., Killackey, M., Kulasingam, S. L., Cain, J. M., Garcia, F. A. R., Moriarty, A. T., Waxman, A. G., Wilbur, D. C., et al. (2012) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0b013e31824ca9d5 · Cited by 915
Self-citation
Research works printed but not linked: 1
- Provencher DM, 2008, J Obstet Gynaecol Can, 8, 15
Cited by
Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women
Clarke, M. A., Long, B. J., Del Mar Morillo, A., Arbyn, M., Bakkum-Gamez, J. N., & Wentzensen, N. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.2820 · Cited by 426
Self-citationArbyn, M., Redman, C. W. E., Verdoodt, F., Kyrgiou, M., Tzafetas, M., Ghaem-Maghami, S., Petry, K.-U., Leeson, S., Bergeron, C., Nieminen, P., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30700-3 · Cited by 342
Self-citation2020 list of human papillomavirus assays suitable for primary cervical cancer screening
Arbyn, M., Simon, M., Peeters, E., Xu, L., Meijer, C. J. L. M., Berkhof, J., Cuschieri, K., Bonde, J., Ostrbenk Vanlencak, A., Zhao, F.-H., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.04.031 · Cited by 284
Self-citationCuschieri, K., Ronco, G., Lorincz, A., Smith, L., Ogilvie, G., Mirabello, L., Carozzi, F., Cubie, H., Wentzensen, N., Snijders, P., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31261 · Cited by 171
Self-citationFive-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women
Clarke, M. A., Cheung, L. C., Castle, P. E., SCHIFFMAN, M. H., Tokugawa, D., Poitras, N. E., Lorey, T. S., Kinney, W., & Wentzensen, N. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4270 · Cited by 147
Self-citationCheung, L. C., Egemen, D., Chen, X., Katki, H. A., Demarco, M., Wiser, A. L., Perkins, R. B., Guido, R. S., Wentzensen, N., & SCHIFFMAN, M. H. (2020) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000528 · Cited by 127
Self-citationClarke, M. A., & Wentzensen, N. (2018) · Cancer Cytopathology · doi:10.1002/cncy.22018 · Cited by 119
Self-citationOu, Y.-C., Fu, H.-C., Tseng, C.-W., Wu, C.-H., Tsai, C.-C., & Lin, H. (2019) · BMC Women's Health · doi:10.1186/s12905-019-0798-y · Cited by 87
Bowden, S. J., Kalliala, I. E. J., Veroniki, A. A., Arbyn, M., Mitra, A., Lathouras, K., Mirabello, L. J., Chadeau‐Hyam, M., Paraskevaidis, E. A., Flanagan, J. M., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.10.053 · Cited by 97
“In this scenario, re-test probabilities would be lower [18] and the value of methyation testing would increase.”
BackgroundMethodSelf-citationHashim, D., Engesæter, B. Ø., Skare, G. B., Castle, P. E., Bjørge, T., Tropé, A., & Nygård, M. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0790-1 · Cited by 101
Peeters, E., Wentzensen, N., Bergeron, C., & Arbyn, M. (2019) · Cancer Cytopathology · doi:10.1002/cncy.22103 · Cited by 66
Self-citationSmith, M. A., Sherrah, M., Sultana, F., Castle, P. E., Arbyn, M., Gertig, D. M., Caruana, M., Wrede, C. D., Saville, M., & Canfell, K. (2022) · BMJ · doi:10.1136/bmj-2021-068582 · Cited by 70
Self-citationStanczuk, G. A., Baxter, G., Currie, H. D., Forson, W., LAWRENCE, J. R., Cuschieri, K. S., Wilson, A., Patterson, L., Govan, L., Black, J., et al. (2017) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0534 · Cited by 55
Self-citationTao, X., Austin, R. M., Yu, T. C., Zhong, F., Zhou, X., Cong, Q., Sui, L., & Zhao, C. (2021) · Cancer Cytopathology · doi:10.1002/cncy.22536 · Cited by 52
Bonde, J., Ejegod, D. M., Cuschieri, K., Dillner, J., Heideman, D. A. M., Quint, W., Pavon Ribas, M. A., Padalko, E., Christiansen, I. K., Xu, L., et al. (2018) · Journal of Clinical Virology · doi:10.1016/j.jcv.2018.09.012 · Cited by 44
Self-citationUpdated evidence-based recommendations for cervical cancer screening in France
Hamers, F. F., Poullié, A.-I., & Arbyn, M. (2021) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000701 · Cited by 40
“The role of co-testing (systematic use of both cytology and HPV test) was not considered as the potential benefit of co-testing versus HPV test alone is extremely small and this strategy has been shown to be inefficient (Arbyn et al., 2012; Schiffman et al., 2018).”
MethodSelf-citationA prospective study of risk-based colposcopy demonstrates improved detection of cervical precancers
Wentzensen, N., Walker, J. L., Smith, K., Gold, M. A., Zuna, R. E., Massad, L. S., Liu, A. H.-C., Silver, M. I., Dunn, S. T., & SCHIFFMAN, M. H. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.02.009 · Cited by 32
Self-citationTriage of HPV-positive women in Norway using cytology, HPV16/18 genotyping and HPV persistence
Arbyn, M., Rezhake, R., Yuill, S., & Canfell, K. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0787-9 · Cited by 36
Self-citationMistro, A. D., Adcock, R., Carozzi, F., Gillio‐Tos, A., Marco, L. D., Girlando, S., Rizzolo, R., Frayle, H., Trevisan, M., Sani, C., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31326 · Cited by 29
“warranted for a risk >10%, different and country-specific decision thresholds do exist for risk levels in the 1–10% range.(43) Combining genotyping with other triage methods (e.”
Self-citationRezhake, R., Chen, F., Hu, S., Zhao, X., Zhang, X., Cao, J., Qiao, Y., Zhao, F., & Arbyn, M. (2020) · International Journal of Cancer · doi:10.1002/ijc.33001 · Cited by 25
“7%) Age of sexual debut Median (range), years 21 (15-29) 21 (17-25) .”
Self-citationStoler, M. H., Parvu, V., Yanson, K. A., Andrews, J. C., & Vaughan, L. M. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.04.022 · Cited by 32
Xue, H., Gao, H., Zheng, J., Chen, Y., Chen, J., Pan, D., Dong, B., & Sun, P. (2021) · Journal of Cancer · doi:10.7150/jca.55826 · Cited by 24
“Previous reports had focused mainly on HR-HPV or HPV 16/18 [30-32], or investigated a population with cytology as a primary screening method.”
MethodDun, C., Yuan, M., Zhao, X., Hu, S., Arbyn, M., & Zhao, F. (2024) · Cancer Medicine · doi:10.1002/cam4.7316 · Cited by 26
Self-citationBeta-binomial analysis of variance model for network meta-analysis of diagnostic test accuracy data
Nyaga, V. N., Arbyn, M., & Aerts, M. (2016) · Statistical Methods in Medical Research · doi:10.1177/0962280216682532 · Cited by 27
Self-citationVintermyr, O. K., Andersland, M. S., Bjørge, T., Skar, R., Iversen, O. E., Nygård, M., & Haugland, H. K. (2018) · International Journal of Cancer · doi:10.1002/ijc.31390 · Cited by 25
Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework
Dhillon, S. K., Oštrbenk, A., Xu, L., Poljak, M., & Arbyn, M. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00286-21 · Cited by 26
“It clearly showed that the presence of HPV-16/18 justifies immediate referral to colposcopy, and that women with LSIL carrying other HPV types cannot be returned to routine screening and require further active monitoring (39, 40).”
BackgroundSelf-citationNowakowski, A. M., Arbyn, M., Turkot, M. H., Wieszczy, P., Miłosz, K., Kaminski, M. F., Didkowska, J. A., Bidziński, M., Olszewski, W. T., Wielgoś, M., et al. (2019) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000528 · Cited by 19
“5%) and a positive triage should rise this risk over a level where referral is justified (for instance with a positive predictive value (PPV) of >10%) (Arbyn et al., 2017).”
BackgroundSelf-citationEjegod, D. M., Hansen, M., Christiansen, I. K., Pedersen, H., Quint, W. G. V., Xu, L., Arbyn, M., & Bonde, J. H. (2020) · Journal of Clinical Virology · doi:10.1016/j.jcv.2020.104336 · Cited by 18
Self-citationXu, L., Benoy, I. H., Cuschieri, K. S., Poljak, M., Bonde, J. H., & Arbyn, M. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1613890 · Cited by 17
“How the sensitivity and specificity of HPV16/18 genotyping change between crosssectional or longitudinal endpoint has been assessed in a previously published meta-analysis [4].”
InfluentialSelf-citationDong, B., Zou, H., Mao, X., Su, Y., Gao, H., Xie, F., Lv, Y., Chen, Y., Kang, Y., Xue, H., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211010939 · Cited by 16
Molecular triaging options for women testing HPV positive with self-collected samples
Taghavi, K., Zhao, F., Downham, L., Baena, A., & Basu, P. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1243888 · Cited by 17
Dong, B., Chen, L., Lin, W., Su, Y., Mao, X., Pan, D., Ruan, G., Xue, H., Kang, Y., & Sun, P. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01512-4 · Cited by 16
Polman, N. J., Veldhuijzen, N. J., Heideman, D. A. M., Snijders, P. J. F., Meijer, C. J. L. M., & Berkhof, J. H. (2018) · International Journal of Cancer · doi:10.1002/ijc.32004 · Cited by 13
Ejegod, D. M., Lagheden, C., Bhatia, R., Pedersen, H., Boada, E. A., Sundström, K., Cortés, J., José, F. X. B., Cuschieri, K. S., Dillner, J., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06888-0 · Cited by 13
Mazurec, K., Trzeszcz, M., Mazurec, M., Streb, J., Hałoń, A., & Jach, R. (2023) · Cancers · doi:10.3390/cancers15205095 · Cited by 14
“Due to the relationship between PPV and disease prevalence, it may differ across populations [42].”
BackgroundGori, S., Battagello, J., Gustinucci, D., Campari, C., Zorzi, M., Frayle, H., Passamonti, B. U., Sartori, G., Bulletti, S., Fodero, C., et al. (2020) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.16631 · Cited by 16
Stanczuk, G., Currie, H., Forson, W., Baxter, G., Lawrence, J., Wilson, A., Palmer, T., Arbyn, M., & Cuschieri, K. S. (2022) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-21-1425 · Cited by 13
Self-citationRatnam, S., Jang, D., Gilbert, L., Alaghehbandan, R., Schell, M., Needle, R. F., Ecobichon-Morris, A., Wang, P., Rahman, M., Costescu, D., et al. (2020) · Papillomavirus Research · doi:10.1016/j.pvr.2020.100206 · Cited by 13
“It is important, however, to point out while testing for genotypes 16/18 increases efficiency, it is significantly less sensitive than testing for hr-HPV as shown in our study (Tables 3 and 5) and consistent with the data reported in the meta-analysis [28].”
BackgroundMethodResultInfluentialLeeson, S. C., Alalade, R., Singh, N., Nieminen, P., Cruickshank, M. E., Carcopino, X., & Bergeron, C. (2021) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2020.12.061 · Cited by 11
Wang, J., Dong, J., Zhou, Y., Wang, K., Pan, M., Deng, Z., Wang, P., Du, Y., & Lü, W. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.12.033 · Cited by 9
Profile of MeltPro® HPV test for human papillomavirus genotyping and cervical precancer screening
Liao, Y., & Li, Q. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1662299 · Cited by 8
Profile of the BD HPV OnclarityTM assay
Bottari, F., & Iacobone, A. D. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1622415 · Cited by 11
“Since most of the invasive cervical carcinomas (about 70%) have been caused by HPV16 and HPV18, individual reporting of these two genotypes has been employed as part of clinical management of HPV-patients, through the concept of ‘risk stratification’ [19,20].”
MethodBomans, L., Ramírez, A. T., Hillemanns, P., Gültekin, M., & Arbyn, M. (2025) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005997 · Cited by 11
Self-citationGilbert, L., Ratnam, S., Jang, D., Alaghehbandan, R., Schell, M., Needle, R., Ecobichon-Morris, A., Wadhawan, A., Costescu, D., Elit, L., et al. (2022) · Cancer Biomarkers · doi:10.3233/cbm-210366 · Cited by 9
Attoeva, D. I., Asaturova, A. V., Prilepskaya, V. N., Starodubtseva, N. L., Леонидовна, Ш. П., & Тимуровна, У. А. (2021) · GYNECOLOGY · doi:10.26442/20795696.2021.1.200647 · Cited by 5
Ellis, L. B., Tighe, J., Bowden, S. J., Kechagias, K. S., Paraskevaidi, M., Garg, A., Paraskevaidis, E., Arbyn, M., Veroniki, A. A., Kalliala, I. E. J., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116823 · Cited by 8
Self-citationRufail, M. L., Lew, M., Pang, J. C., Jing, X., Heider, A., & Cantley, R. (2020) · Journal of the American Society of Cytopathology · doi:10.1016/j.jasc.2020.02.003 · Cited by 4
Giray, B., Kabaca, C., Uzun, M. G., Akış, S., Purut, Y. E., Keleş, E., & Çetiner, H. (2020) · Diagnostic Cytopathology · doi:10.1002/dc.24633 · Cited by 4
Rezhake, R., Wang, Y., Chen, F., Hu, S., Zhang, X., Cao, J., Qiao, Y., Zhao, F., & Arbyn, M. (2021) · Cancer Cytopathology · doi:10.1002/cncy.22428 · Cited by 5
Self-citationChadha, S., Gandhi, G., Hedau, S. T., & Gupta, R. (2023) · The Journal of Obstetrics and Gynecology of India · doi:10.1007/s13224-022-01731-x · Cited by 3
Prevalence and genotype distribution of human papillomavirus infection among Kurdish people, Iran
Nikkhoo, B., Mahmoodian, S., Bahrami, P., Daraee, A., Soleimani, F., Zamani, F., Nasseri, S., & Rahmani, K. (2025) · SAGE Open Medicine · doi:10.1177/20503121251320522 · Cited by 3
“It 22–24 Among the 41 genotypes investigated in our study, the most common genotypes were 6, 16, and 54, with frequencies of 197 (30.1%), 94 (14.4%), and 59 (9%), respectively.”
InfluentialKong, L., Xiao, X., Wan, R., Zhao, S., & Wang, W. (2025) · BMC Cancer · doi:10.1186/s12885-025-14972-6 · Cited by 4
“And the multivariate logistic regression analysis indicated that the immediate risk of CIN2 + and CIN3 + in HPV 16/18 + group was 2.85 times and 3.09 times, respectively, when compared to the HPV other + group ( P <0.05), which was similar with the study of Lin et al. [19] and Arbyn et al. [27].”
InfluentialChen, Y., Liu, L., Chen, Y., Wang, Y., & Yan, Y. (2026) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2026.105463 · Cited by 2
Preliminary outcomes of the Cervical Cancer Screening Program of Northern Portugal: A snapshot
Salta, S., Sequeira, J. P., Lobo, J., Sousa, A. R., de Sousa, H. M. L., Baldaque, I., Monteiro, P., Tavares, F., Henrique, R., & Jerónimo, C. (2024) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2024.04.020 · Cited by 3
HPV infection screening using surface plasmon resonance in women from Kunming (southwest China)
Liu, Y., Quan, Y., Xu, C., Huang, Y., Li, D., Qing, Q., Sun, C., & Zhou, H. (2019) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2019.4352 · Cited by 2
“Cervical cytology combined with HPV DNA testing appears to have high sensitivity but low specificity for detecting cervical intraepithelial neoplasia (CIN)3 or worse [19] and for identifying women with low-grade lesions requiring a biopsy [20].”
BackgroundRole of human papillomavirus genotyping in cervical cancer screening
Andújar, M. (2023) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimce.2022.11.022 · Cited by 3
Triage of Women With ASCUS and LSIL Abnormal Cytology: The ALTS Experience and Beyond
Lorincz, A. T., Wheeler, C. M., & Arbyn, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814457-2.00015-5 · Cited by 2
Self-citationChen, S., Dai, H., Hu, S., Gao, T., Chen, M., Zhou, X., Dai, L., Zhao, X., & Zhao, F. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06822-7 · Cited by 1
“Decision thresholds were based on benchmark risk levels applied in the United States [23] and Europe [24].”
Zhao, X., Hu, S., Zhao, S., Rezhake, R., Huang, L., Duan, X., Zhang, X., Qiao, Y., Arbyn, M., & Zhao, F. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.08.002 · Cited by 1
“16 In accordance with the previous guideline or publication using physician-samples, 21 , 22 immediate colposcopy or treat-ment should be given to women positive for HPV 16/18 (particularly E6 oncoprotein) considering the fact that their IRs were higher than 4%.”
MethodSelf-citationRole of human papillomavirus genotyping in cervical cancer screening
Andújar, M. (2023) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2022.11.007 · Cited by 2
Mitamura, T., Konno, Y., Kikawa, S., Iwaki, Y., Iwaki, K., Tanuma, F., & Kataoka, S. (2019) · Journal of Cytology · doi:10.4103/joc.joc_148_17 · Cited by 1
“[10,14,18] A previous meta-analysis showed that the average risk for a high-grade cervical lesion is higher in HPV-16- and HPV-18-positive women with ASC-US than in HR-HPV-positive but HPV-16- and HPV-18-negative women with ASC-US.[19] However, more recent reports have shown that infection with non-16/18-HR-HPVs is mo…”
ResultInfluentialМирзоевна, Н. Н., Gusakov, K. I., & Геннадьевна, С. Е. (2019) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2019-7-34-38 · Cited by 1
Xu, X., Rezhake, R., Hu, S., Chen, F., Zhang, X., Pan, Q., Zhang, W., Ma, J., Qiao, Y., Zhao, F., et al. (2020) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0456 · Cited by 1
“Considering the CIN2þ prevalence endpoint used in this study and according to a previous triage analysis in Chinese women, we adopted the intermediate benchmark risk levels proposed by Arbyn and colleagues (NPV at 98% and PPV at 20%) to reevaluate triage strategies in managing HPV-positive women at the fourth screenin…”
BackgroundMethodPedersen, K. (2018) · NORA - Norwegian Open Research Archives
Precáncer anogenital: nuevos horizontes para el ginecólogo
Peralta, J., Rios, J. A. L., & Arcos, H. F. A. (2020) · Cited by 2
Possibilities and prospects of cervical screening
Kaptilnyy, V. A., Poznyak, M. V., Chilova, R., Lystsev, D., & Savelyeva, M. I. (2024) · Vrach · doi:10.29296/25877305-2024-11-01
Bonde, J. H., Schroll, J. B., Pedersen, B. T., Lynge, E., Waldstrøm, M., Viborg, P. H., Frandsen, A. P., Andersen, R. H., Nielsen, S., Schledermann, D., et al. (2026) · International Journal of Cancer · doi:10.1002/ijc.70502 · Cited by 1
Eficacia y coste-efectividad de incluir el genotipado de VPH en el cribado de cáncer de cérvix
Gutiérrez-Pizarraya, A., Márquez, J. M. M., López, R. R., Blasco‐Amaro, J. A., Sánchez, F. J., García-Agua-Soler, N., González-Álvarez, M. L., & García-Ruiz, A. J. (2026) · doi:10.52766/nwdq7431
Metadata
- Authors
- Arbyn, M., Xu, L., Verdoodt, F., Cuzick, J., Szarewski, A., Belinson, J. L., Wentzensen, N., Gage, J. C., & Khan, M. J.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2017-01-17
- Volume
- 166
- Issue
- 2
- Pages
- 118-127
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2551830992
- Cited by
- 68
- References
- 57
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 5 · 2021: 9 · 2020: 13 · 2019: 11 · 2018: 10 · 2017: 2
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Funders
- The Belgian Foundation Against Cancer, Brussels, Belgium
- Seventh Framework Programme of DG Research of the European Commission, through the COHEAHR Network (603019)
- Topics
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
- Keywords
- human papillomavirus, HPV16, HPV 18, HPV genotyping, cervical intraepithelial neoplasia, ASCUS, low-grade squamous intraepithelial lesion, cervical cancer screening, triage, high-risk HPV testing, sensitivity and specificity, colposcopy referral, risk stratification
- MeSH terms
- Uterine Cervical Neoplasms, Female, Genotype, Humans, Precancerous Conditions, Risk Factors, Sensitivity and Specificity, Triage, Papillomavirus Infections, Human papillomavirus 18, Human papillomavirus 16, Early Detection of Cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.